Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO-STEMI
NCT07749014Phase 2Not yet recruiting
- Sponsor
- Rehman Medical Institute
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in ST elevation myocardial infarction (STEMI), sponsored by Rehman Medical Institute. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT07749014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749014.